Pictet Asset Management Holding SA Sells 322,580 Shares of Janux Therapeutics, Inc. $JANX

Key Points

• Pictet Asset Management sold 322,580 shares of Janux Therapeutics, reducing its stake by 54.2% to 272,251 shares (about 0.45% of the company) worth roughly $3.76 million per its latest 13F filing.
• Several analysts have cut ratings and price targets recently — including Barclays (to underweight, $14) and reductions from Cantor Fitzgerald, Guggenheim and Piper Sandler — yet the consensus remains a Moderate Buy with an average target of $49.75.
• Janux beat Q4 expectations with EPS of ($0.51) vs. ($0.65) est. and revenue of $7.88M well above forecasts; the stock trades near $14.34, with a 12‑month range of $12.12–$35.34 and a market cap of $874.2M.

Pictet Asset Management Holding SA cut its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 54.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 272,251 shares of the company's stock after selling 322,580 shares during the quarter. Pictet Asset Management Holding SA owned approximately 0.45% of Janux Therapeutics worth $3,757,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the business. Aberdeen Group plc lifted its holdings in Janux Therapeutics by 21.1% in the 3rd quarter. Aberdeen Group plc now owns 345,476 shares of the company's stock worth $8,443,000 after buying an additional 60,188 shares during the period. Readystate Asset Management LP raised its holdings in shares of Janux Therapeutics by 38.0% during the third quarter. Readystate Asset Management LP now owns 960,379 shares of the company's stock valued at $23,472,000 after acquiring an additional 264,423 shares in the last quarter. SG Americas Securities LLC lifted its stake in Janux Therapeutics by 175.1% in the fourth quarter. SG Americas Securities LLC now owns 79,817 shares of the company's stock worth $1,101,000 after acquiring an additional 50,802 shares during the period. Rhenman & Partners Asset Management AB boosted its holdings in Janux Therapeutics by 81.6% in the third quarter. Rhenman & Partners Asset Management AB now owns 100,127 shares of the company's stock valued at $2,447,000 after acquiring an additional 45,000 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky bought a new stake in Janux Therapeutics in the fourth quarter valued at $536,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Cantor Fitzgerald decreased their price objective on shares of Janux Therapeutics from $150.00 to $100.00 and set an "overweight" rating for the company in a report on Friday, February 27th. Weiss Ratings raised shares of Janux Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, April 22nd. Guggenheim decreased their price target on shares of Janux Therapeutics from $72.00 to $68.00 and set a "buy" rating for the company in a research note on Friday, February 27th. Piper Sandler lowered their price objective on shares of Janux Therapeutics from $42.00 to $30.00 and set an "overweight" rating for the company in a report on Friday, January 16th. Finally, Barclays cut Janux Therapeutics from an "overweight" rating to an "underweight" rating and cut their price objective for the company from $29.00 to $14.00 in a research report on Monday, April 20th. Ten analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $49.75.

Janux Therapeutics Stock Performance

Shares of Janux Therapeutics stock opened at $14.34 on Monday. Janux Therapeutics, Inc. has a 12 month low of $12.12 and a 12 month high of $35.34. The firm has a market capitalization of $874.20 million, a P/E ratio of -7.84 and a beta of 2.58. The business has a fifty day simple moving average of $14.29 and a two-hundred day simple moving average of $17.72.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its earnings results on Thursday, February 26th. The company reported ($0.51) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.14. The business had revenue of $7.88 million during the quarter, compared to analysts' expectations of $0.08 million. Analysts predict that Janux Therapeutics, Inc. will post -2.34 earnings per share for the current year.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.

Want to see what other hedge funds are holding JANX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.